down arrow

Harvard Bioscience, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4169061052
  • NASDAQ: HBIO
USD
8.02
-0.03 (-0.37%)

Sep 24

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Bioventus, Inc.
Standard BioTools, Inc.
Butterfly Network, Inc.
908 Devices, Inc.
Axogen, Inc.
Pulse Biosciences, Inc.
TELA Bio, Inc.
Harvard Bioscience, Inc.
Allurion Technologies, Inc.
Celcuity, Inc.
Jin Medical International Ltd.

Why is Harvard Bioscience, Inc. ?

1
Poor Management Efficiency with a low ROCE of 0.93%
  • The company has been able to generate a Return on Capital Employed (avg) of 0.93% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -3.25% over the last 5 years
3
The company has declared Negative results for the last 3 consecutive quarters
  • INTEREST(HY) At USD 3.52 MM has Grown at 121.03%
  • OPERATING CASH FLOW(Y) Lowest at USD 0.95 MM
  • NET PROFIT(HY) At USD -5.78 MM has Grown at -37.41%
4
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 66.18%, its profits have risen by 22.7%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Harvard Bioscience, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Harvard Bioscience, Inc.
79.14%
0.19
975.52%
S&P 500
16.06%
1.20
13.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-3.25%
EBIT Growth (5y)
-5.84%
EBIT to Interest (avg)
-0.06
Debt to EBITDA (avg)
7.24
Net Debt to Equity (avg)
2.15
Sales to Capital Employed (avg)
1.27
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
79.76%
ROCE (avg)
0.93%
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.59
EV to EBIT
50.56
EV to EBITDA
8.42
EV to Capital Employed
1.19
EV to Sales
0.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.24%
ROE (Latest)
-58.40%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET PROFIT(HY)

Higher at USD -5.78 MM

RAW MATERIAL COST(Y)

Fallen by -2.51% (YoY

CASH AND EQV(HY)

Highest at USD 13.6 MM

-21What is not working for the Company
INTEREST(HY)

At USD 3.52 MM has Grown at 121.03%

OPERATING CASH FLOW(Y)

Lowest at USD 0.95 MM

NET PROFIT(HY)

At USD -5.78 MM has Grown at -37.41%

DEBT-EQUITY RATIO (HY)

Highest at 508.26 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.8 times

Here's what is working for Harvard Bioscience, Inc.

Net Profit
Higher at USD -5.78 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Cash and Eqv
Highest at USD 13.6 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by -2.51% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Harvard Bioscience, Inc.

Interest
At USD 3.52 MM has Grown at 121.03%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Profit
At USD -5.78 MM has Grown at -37.41%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD 0.95 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debt-Equity Ratio
Highest at 508.26 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio
Lowest at 1.8 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Footer loading